[{"id":"335041a2-cf72-4beb-950a-50b3ecd1dce6","acronym":"KEYNOTE A99","url":"https://clinicaltrials.gov/study/NCT04198766","created_at":"2021-01-18T20:27:39.735Z","updated_at":"2025-02-25T16:09:43.736Z","phase":"Phase 1/2","brief_title":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)","source_id_and_acronym":"NCT04198766 - KEYNOTE A99","lead_sponsor":"Inhibrx Biosciences, Inc","biomarkers":" EGFR • PD-L1 • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 333","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 02/02/2026","primary_completion_date":" 02/02/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2024-07-19"},{"id":"6b25190a-451d-47e6-90b5-2c15cef6b530","acronym":"","url":"https://clinicaltrials.gov/study/NCT04730843","created_at":"2021-01-29T12:55:15.412Z","updated_at":"2024-07-02T16:35:07.355Z","phase":"Phase 1","brief_title":"A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04730843","lead_sponsor":"Elpiscience Biopharma, Ltd.","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ordastobart (INBRX-106)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-04-26"},{"id":"0807bec8-e806-4b1e-9fd8-795c175d7e88","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991506","created_at":"2021-08-05T13:53:03.898Z","updated_at":"2024-07-02T16:35:50.074Z","phase":"Phase 1","brief_title":"A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04991506","lead_sponsor":"Elpiscience Biopharma, Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ordastobart (INBRX-106)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-04-19"}]